Esperion Therapeutics

$27.02
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.04 (+0.15%) Today
$0.00 (0.00%) As of 5:00 PM EST after-hours

Why Robinhood?

You can buy or sell ESPR and other stocks, options, and ETFs commission-free!

About ESPR

Esperion Therapeutics, Inc. engages in the development and commercialization of oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol. It offers NEXLETOL (bempedoic acid) tablets, and NEXLIZET (bempedoic acid and ezetimibe) tablets. The company was founded by Roger S. Newton, Hans Ageland, Jan O. Johansson, Anders Paul Wiklund, Michael E. Pape, David I. Scheer and Charles L. Bisgaier in May 1998 and is headquartered in Ann Arbor, MI. The listed name for ESPR is Esperion Therapeutics, Inc. Common Stock.

CEO
Tim M. Mayleben
Employees
193
Headquarters
Ann Arbor, Michigan
Founded
1998
Market Cap
753.23M
Price-Earnings Ratio
Dividend Yield
Average Volume
613.28K
High Today
$27.88
Low Today
$26.85
Open Price
$27.16
Volume
326.85K
52 Week High
$76.98
52 Week Low
$23.90

Collections

ESPR Earnings

-$3.41
-$0.83
$1.74
$4.32
Q1 FY19
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
per share
Actual
Expected Feb 25, After Hours

You May Also Like